Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
atopic dermatitis
Biotech
Talawar heads to Nasdaq via SPAC deal to fund eczema bispecific
Talawar Therapeutics is merging with a special purpose acquisition company to go public and support its lead atopic dermatitis asset.
Will Maddox
Jun 29, 2026 7:00am
AbbVie inks $10.9B Apogee buyout to bag eczema prospect
Jun 22, 2026 7:59am
Windward breezes toward phase 3 with $165M for TSLP ambitions
May 4, 2026 10:31am
Sanofi bispecific sees respiratory ph. 2 wins, eczema fail
Apr 7, 2026 4:10am
Connect’s Dupixent rival hits the mark in phase 3 eczema trial
Mar 30, 2026 9:32am
Apogee data drive hype as threat to Lilly, Sanofi becomes clear
Mar 23, 2026 9:00am
